The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-12-22
DOI
10.1038/s41573-021-00345-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells
- (2021) Simon J Dovedi et al. Cancer Discovery
- Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study
- (2021) Thomas A Rasmussen et al. CLINICAL INFECTIOUS DISEASES
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- (2021) E. A. Rozeman et al. NATURE MEDICINE
- Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
- (2021) Helena Van Damme et al. Journal for ImmunoTherapy of Cancer
- Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy
- (2021) Oliver Klein et al. CANCER CELL
- “Dangling” Accelerated Approvals in Oncology
- (2021) Julia A. Beaver et al. NEW ENGLAND JOURNAL OF MEDICINE
- CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
- (2021) Jedd D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
- (2021) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
- (2020) Kazushige Yoshida et al. BMC CANCER
- Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
- (2020) Nicolas Palaskas et al. Journal of the American Heart Association
- Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
- (2020) Laura Strauss et al. Science Immunology
- T Cell Dysfunction and Exhaustion in Cancer
- (2020) Zhen Zhang et al. Frontiers in Cell and Developmental Biology
- PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15
- (2020) Kyung Hwan Kim et al. Cellular & Molecular Immunology
- Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
- (2020) Jean-Christophe Beltra et al. IMMUNITY
- Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.
- (2020) Martin Gutierrez et al. JOURNAL OF CLINICAL ONCOLOGY
- How to select IgG subclasses in developing anti-tumor therapeutic antibodies
- (2020) Jifeng Yu et al. Journal of Hematology & Oncology
- Learning from clinical trials of neoadjuvant checkpoint blockade
- (2020) Judith M. Versluis et al. NATURE MEDICINE
- Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
- (2020) Robert D. Carlson et al. Toxins
- Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
- (2020) Luisa Chocarro de Erauso et al. Frontiers in Pharmacology
- The Role of PD-1 in Acute and Chronic Infection
- (2020) Jil M. Jubel et al. Frontiers in Immunology
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex
- (2020) Sarah C. Garrett-Thomson et al. PLoS One
- Tim-3 finds its place in the cancer immunotherapy landscape
- (2020) Nandini Acharya et al. Journal for ImmunoTherapy of Cancer
- ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
- (2020) P. Baas et al. Journal of Thoracic Oncology
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Antibody engineers seek optimal drug targeting TIGIT checkpoint
- (2020) Elie Dolgin NATURE BIOTECHNOLOGY
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
- (2020) Cinzia Solinas et al. Translational Oncology
- Revisiting the PD-1 pathway
- (2020) Nikolaos Patsoukis et al. Science Advances
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Infiltrating Natural Killer Cells
- (2020) Beatriz Cózar et al. Cancer Discovery
- KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
- (2020) Rupal S. Bhatt et al. Cancer Immunology Research
- Cancer Immunotherapy and the Nectin Family
- (2020) Robert J. Johnston et al. Annual Review of Cancer Biology-Series
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
- (2019) E. Dodagatta-Marri et al. Journal for ImmunoTherapy of Cancer
- PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals
- (2019) Rémi Fromentin et al. Nature Communications
- T cell stemness and dysfunction in tumors are triggered by a common mechanism
- (2019) Suman Kumar Vodnala et al. SCIENCE
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Immune Checkpoint Inhibition in Sepsis
- (2019) Richard S. Hotchkiss et al. CRITICAL CARE MEDICINE
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
- (2019) changhua ji et al. CLINICAL CANCER RESEARCH
- Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway
- (2019) Craig Fenwick et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
- (2019) Irene Cortese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab
- (2019) Ondine Walter et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
- (2019) Miren Zuazo et al. EMBO Molecular Medicine
- Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study
- (2019) Edward Gane et al. JOURNAL OF HEPATOLOGY
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
- (2019) Trine Vilsbøll Larsen et al. Cancer Communications
- PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic SIV-infected macaques on antiretroviral therapy
- (2019) Elena Bekerman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
- (2019) Rui Wang et al. CLINICAL CANCER RESEARCH
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- VISTA is an acidic pH-selective ligand for PSGL-1
- (2019) Robert J. Johnston et al. NATURE
- The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
- (2019) Jiajing Cai et al. OncoTargets and Therapy
- Mechanisms regulating PD-L1 expression on tumor and immune cells
- (2019) Shuming Chen et al. Journal for ImmunoTherapy of Cancer
- PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
- (2019) Yunlong Zhao et al. IMMUNITY
- Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
- (2019) William H. Hudson et al. IMMUNITY
- CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and Cancer
- (2019) Ryan Zander et al. IMMUNITY
- The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
- (2019) Elliot A. Philips et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
- (2018) Vanessa A. Evans et al. AIDS
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
- (2018) Jeremy D. Waight et al. CANCER CELL
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma
- (2018) Bianca Simon et al. EXPERIMENTAL DERMATOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non–Small Cell Lung Cancer
- (2018) Daisuke Shibahara et al. Journal of Thoracic Oncology
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors
- (2018) Wei Wei et al. MEDICINE
- The promise and challenges of immune agonist antibody development in cancer
- (2018) Patrick A. Mayes et al. NATURE REVIEWS DRUG DISCOVERY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
- (2018) Scott Balsitis et al. PLoS One
- Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
- (2018) Randi B. Gombos et al. PLoS One
- Role of PD-1 during effector CD8 T cell differentiation
- (2018) Eunseon Ahn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
- (2018) Yunlong Zhao et al. Cell Reports
- PD-L1 binds to B7-1 only in cis on the same cell surface
- (2018) Apoorvi Chaudhri et al. Cancer Immunology Research
- Human Endothelial Cells Modulate CD4+ T Cell Populations and Enhance Regulatory T Cell Suppressive Capacity
- (2018) Wen Chean Lim et al. Frontiers in Immunology
- Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
- (2018) Adrien Costantini et al. OncoImmunology
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Cancer immunologists scoop medicine Nobel prize
- (2018) Heidi Ledford et al. NATURE
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
- (2018) Marcin Kowanetz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
- (2017) Marija Mojic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
- (2017) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
- (2017) Cynthia L. Gay et al. JOURNAL OF INFECTIOUS DISEASES
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
- (2017) Udupi A. Ramagopal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- Transcription Factor T-bet Orchestrates Lineage Development and Function in the Immune System
- (2017) Axel Kallies et al. TRENDS IN IMMUNOLOGY
- Masterful Antibodies: Checkpoint Blockade
- (2017) Nils Lonberg et al. Cancer Immunology Research
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
- (2017) Sarah Chuzi et al. Cancer Management and Research
- Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
- (2017) O. Hamid et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme
- (2017) Brittany A. Goods et al. PLoS One
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
- (2016) Patrizio Caturegli et al. AMERICAN JOURNAL OF PATHOLOGY
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
- (2016) Zhenkun Na et al. CELL RESEARCH
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
- (2016) Roberto Tinoco et al. IMMUNITY
- T Cell Factor 1-Expressing Memory-like CD8 + T Cells Sustain the Immune Response to Chronic Viral Infections
- (2016) Daniel T. Utzschneider et al. IMMUNITY
- Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4 + T Cell Immunity
- (2016) Deshapriya S. Karunarathne et al. IMMUNITY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- CD4+T cell effector commitment coupled to self-renewal by asymmetric cell divisions
- (2016) Simone A. Nish et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Genetic and Epigenetic Regulation of PD-1 Expression
- (2016) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion
- (2016) Eunseon Ahn et al. JOURNAL OF VIROLOGY
- The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia
- (2016) M Qorraj et al. LEUKEMIA
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
- (2016) Ran He et al. NATURE
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
- (2016) Andreas Lundqvist et al. Journal for ImmunoTherapy of Cancer
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Dan R. Littman CELL
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
- (2015) Zeynep Eroglu et al. EUROPEAN JOURNAL OF CANCER
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
- (2015) B. Lo et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Confusing signals: Recent progress in CTLA-4 biology
- (2015) Lucy S.K. Walker et al. TRENDS IN IMMUNOLOGY
- Neoepitopes of Cancers: Looking Back, Looking Ahead
- (2015) P. K. Srivastava Cancer Immunology Research
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
- (2014) Yanping Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CTLA4 Expression Is an Indicator and Regulator of Steady-State CD4+FoxP3+ T Cell Homeostasis
- (2014) A. L. Tang et al. JOURNAL OF IMMUNOLOGY
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- The Immunological Synapse
- (2014) M. L. Dustin Cancer Immunology Research
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
- (2013) Chen Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
- (2013) David Gardiner et al. PLoS One
- Tolerance and exhaustion: defining mechanisms of T cell dysfunction
- (2013) Andrea Schietinger et al. TRENDS IN IMMUNOLOGY
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
- (2012) X. Tai et al. BLOOD
- Properties of mouse and human IgG receptors and their contribution to disease models
- (2012) P. Bruhns BLOOD
- Notch signaling regulates PD-1 expression during CD8+ T-cell activation
- (2012) Mélissa Mathieu et al. IMMUNOLOGY AND CELL BIOLOGY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Responsiveness of HIV-specific CD4 T cells to PD-1 blockade
- (2011) F. Porichis et al. BLOOD
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- 4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection
- (2011) V. Vezys et al. JOURNAL OF IMMUNOLOGY
- Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
- (2011) Noah S Butler et al. NATURE IMMUNOLOGY
- Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
- (2010) Juan Dubrot et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dynamic Equilibrium of B7-1 Dimers and Monomers Differentially Affects Immunological Synapse Formation and T Cell Activation in Response to TCR/CD28 Stimulation
- (2010) Sumeena Bhatia et al. JOURNAL OF IMMUNOLOGY
- CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition
- (2010) D. L. Barber et al. JOURNAL OF IMMUNOLOGY
- Mechanisms of Spatial and Temporal Development of Autoimmune Vitiligo in Tyrosinase-Specific TCR Transgenic Mice
- (2010) Randal K. Gregg et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
- (2010) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- (2010) Axel Hoos et al. SEMINARS IN ONCOLOGY
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
- (2009) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms
- (2009) Wataru Ise et al. NATURE IMMUNOLOGY
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
- (2009) Nicolas Chomont et al. NATURE MEDICINE
- PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis
- (2009) X. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epitope Landscape in Breast and Colorectal Cancer
- (2008) N. H. Segal et al. CANCER RESEARCH
- Interaction of human PD-L1 and B7-1
- (2008) Manish J. Butte et al. MOLECULAR IMMUNOLOGY
- Enhancing SIV-specific immunity in vivo by PD-1 blockade
- (2008) Vijayakumar Velu et al. NATURE
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade
- (2008) S. D. Blackburn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
- CTLA-4 trafficking and surface expression
- (2008) Elke Valk et al. TRENDS IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More